231 related articles for article (PubMed ID: 24398726)
1. Treatment of older patients with high-risk myelodysplastic syndromes (MDS): the emerging role of allogeneic hematopoietic stem cell transplantation (Allo HSCT).
Atallah E; Bylow K; Troy J; Saber W
Curr Hematol Malig Rep; 2014 Mar; 9(1):57-65. PubMed ID: 24398726
[TBL] [Abstract][Full Text] [Related]
2. [Progress of research on allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimen for treatment of myelodysplastic syndrome - review].
Zhang Z; Li X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):969-74. PubMed ID: 18718102
[TBL] [Abstract][Full Text] [Related]
3. Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning.
Yucel OK; Saliba RM; Rondon G; Ahmed S; Alousi A; Bashir Q; Ciurea SO; Popat U; Khouri I; Marin D; Rezvani K; Kebriaei P; Shpall EJ; Champlin RE; Oran B
Cancer; 2017 Jul; 123(14):2661-2670. PubMed ID: 28324640
[TBL] [Abstract][Full Text] [Related]
4. Systemic inflammatory autoimmune disease before allogeneic hematopoietic stem cell transplantation is a risk factor for death in patients with myelodysplastic syndrome or chronic myelomonocytic leukemia.
Tazoe K; Harada N; Makuuchi Y; Kuno M; Takakuwa T; Okamura H; Hirose A; Nakamae M; Nishimoto M; Nakashima Y; Koh H; Hino M; Nakamae H
Ann Hematol; 2024 Jun; 103(6):2059-2072. PubMed ID: 38662207
[TBL] [Abstract][Full Text] [Related]
5. European Group for Blood and Marrow Transplantation score correlates with outcomes of older patients undergoing allogeneic hematopoietic stem cell transplantation.
Chien SH; Liu YC; Liu CJ; Ko PS; Wang HY; Hsiao LT; Lin JS; Chiou TJ; Liu CY; Gau JP
J Chin Med Assoc; 2020 Mar; 83(3):238-244. PubMed ID: 31904659
[TBL] [Abstract][Full Text] [Related]
6. Meta-analysis of the benefit of hypomethylating agents before allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes.
Liu L; Jia M; Sun L; Tian W; Tang P; Jiang Z
Clin Exp Med; 2021 Nov; 21(4):537-543. PubMed ID: 33866494
[TBL] [Abstract][Full Text] [Related]
7. Conditioning Regimen of 5-Day Decitabine Administration for Allogeneic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome and Myeloproliferative Neoplasms.
Cao YG; He Y; Zhang SD; Liu ZX; Zhai WH; Ma QL; Pang AM; Wei JL; Yang DL; Huang Y; Feng SZ; Jiang EL; Han MZ
Biol Blood Marrow Transplant; 2020 Feb; 26(2):285-291. PubMed ID: 31494229
[TBL] [Abstract][Full Text] [Related]
8. Review of stem-cell transplantation for myelodysplastic syndromes in older patients in the context of the Decision Memo for Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome emanating from the Centers for Medicare and Medicaid Services.
Giralt SA; Horowitz M; Weisdorf D; Cutler C
J Clin Oncol; 2011 Feb; 29(5):566-72. PubMed ID: 21220586
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic hematopoietic stem cell transplant in adult patients with myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes.
Sharma P; Shinde SS; Damlaj M; Hefazi Rorghabeh M; Hashmi SK; Litzow MR; Hogan WJ; Gangat N; Elliott MA; Al-Kali A; Tefferi A; Patnaik MM
Leuk Lymphoma; 2017 Apr; 58(4):872-881. PubMed ID: 27687869
[TBL] [Abstract][Full Text] [Related]
10. Optimal positioning of hematopoietic stem cell transplantation for older patients with myelodysplastic syndromes.
Abel GA; Koreth J
Curr Opin Hematol; 2013 Mar; 20(2):150-6. PubMed ID: 23298879
[TBL] [Abstract][Full Text] [Related]
11. [Prognostic impact of circulating tumor DNA status post-allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia and myelodysplastic syndromes].
Yokoyama K
Rinsho Ketsueki; 2021; 62(5):486-495. PubMed ID: 34248126
[TBL] [Abstract][Full Text] [Related]
12. A Randomized Study Comparing Stem Cell Transplantation Versus Conventional Therapy for Low- and Intermediate-Risk Myelodysplastic Syndromes Patients.
Yu ZP; Ding JH; Sun AN; Ge Z; Chen BA; Wu DP
Stem Cells Dev; 2017 Aug; 26(15):1132-1139. PubMed ID: 28494646
[TBL] [Abstract][Full Text] [Related]
13. Myeloablative intravenous busulfan-containing regimens for allo-HSCT in AML or MDS patients over 54 years old: combined results of three phase II studies.
Uchida N; Matsumoto K; Sakura T; Hidaka M; Miyamoto T; Eto T; Maeda Y; Murayama T; Fujishima N; Yoshimoto G; Morita K; Kishimoto J; Teshima T; Taniguchi S; Yamashita T; Mori SI; Akashi K; Harada M;
Int J Hematol; 2020 Oct; 112(4):510-523. PubMed ID: 32656637
[TBL] [Abstract][Full Text] [Related]
14. Pretreatment CD34
Jentzsch M; Geus U; Grimm J; Vucinic V; Pönisch W; Franke GN; Behre G; Niederwieser D; Schwind S
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1560-1566. PubMed ID: 30928626
[TBL] [Abstract][Full Text] [Related]
15. [Outcomes and prognostic factors of myelodysplastic syndrome patients with allogeneic hematopoietic stem cell transplantation].
Liu ZX; Lyu MN; Wang QQ; Zhai WH; Pang AM; Ma QL; Yang DL; He Y; Zhang RL; Huang Y; Wei JL; Feng SZ; Jiang EL; Han MZ
Zhonghua Xue Ye Xue Za Zhi; 2019 Jun; 40(6):484-489. PubMed ID: 31340621
[No Abstract] [Full Text] [Related]
16. Moderate to Severe Marrow Fibrosis As a More Advanced Risk Factor for MDS and MDS-AML Patients With Excess of Blasts Receiving Allogeneic Hematopoietic Stem Cell Transplantation.
Wang J; Wang Q; Zhang H; He Y; Huang Y; Zhang R; Wei J; Ma Q; Pang A; Yang D; Chen X; Jiang E; Feng S; Zhai W; Han M
Transplant Cell Ther; 2021 Aug; 27(8):666.e1-666.e9. PubMed ID: 34020086
[TBL] [Abstract][Full Text] [Related]
17. Hematopoietic stem cell transplantation for myelodysplastic syndrome: a review.
Parmar S; de Lima M; Deeg HJ; Champlin R
Semin Oncol; 2011 Oct; 38(5):693-704. PubMed ID: 21943676
[TBL] [Abstract][Full Text] [Related]
18. Selection of Patients With Myelodysplastic Syndrome for Allogeneic Hematopoietic Stem Cell Transplantation.
Mishra A; Anasetti C
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S49-52. PubMed ID: 27521324
[TBL] [Abstract][Full Text] [Related]
19. Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic/Myeloproliferative Neoplasms-Unclassifiable: A Retrospective Nationwide Study of the Japan Society for Hematopoietic Cell Transplantation.
Kurosawa S; Shimomura Y; Tachibana T; Ishiyama K; Ota S; Kobayashi T; Uchida N; Fukushima K; Ashida T; Matsuoka KI; Kanda J; Ichinohe T; Atsuta Y; Murata M; Aoki J
Biol Blood Marrow Transplant; 2020 Sep; 26(9):1607-1611. PubMed ID: 32454216
[TBL] [Abstract][Full Text] [Related]
20. [Effects of allogeneic hematopoietic stem cell transplantation on 60 patients with myelodysplastic syndrome].
Lu Y; Wu T; Cao XY; Wang JB; Yin YM; Lu DP
Zhonghua Nei Ke Za Zhi; 2010 Mar; 49(3):200-3. PubMed ID: 20450649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
